top of page
이미지 제공: Markus Spiske

Investor Relations

FINANCIAL INFORMATION

CONSOLIDATED BALANCE SHEET

(Unit: million won)

Category
2021
2022
2023
2024
Current Assets (Total)
67,519
75,655
81,929
97,148
Non-Current Assets
45,357
40,184
35,712
33,250
Total Assets
112,877
115,839
117,641
130,398
Current Liabilities
5,766
7,389
4,821
5,863
Non-Current Liabilities
423
358
934
367
Total Liabilities
6,189
7,747
5,755
6,229
Capital Stock
4,700
4,700
4,700
4,700
Capital Surplus
12,760
12,760
12,760
12,760
Retained Earnings
109,894
114,993
118,217
130,264
Total Equity
106,687
108,092
111,885
124,168

CONSOLIDATED INCOME STATEMENT

(Unit: million won)

Category
2021
2022
2023
2024
Sales Revenue
46,873
50,526
53,787
49,913
Gross Profit
35,683
37,951
38,975
36,060
Operating Income
7,257
6,051
2,195
6,796
Income Before Tax
12,090
10,172
6,880
15,610
Net Income
10,383
8,281
6,304
15,127

CONSOLIDATED CASH FLOW STATEMENT

(Unit: million won)

Category
2021
2022
2023
2024
Cash Flows from Operating Activities
14,892
12,814
7,815
19,267
Cash Flows from Investing Activities
-11,132
-6,669
-4,745
-18,737
Cash Flows from Financing Activities
-3,858
-7,538
-3,721
-3,741
Increase (Decrease) in Cash
260
-1,402
-574
-3,128
Beginning Cash Balance
9,600
9,860
8,458
7,884
Ending Cash Balance
9,860
8,458
7,884
4,757

DISCLOSURE

Date
Report Name
보고서명
Submitter
15/12/2025
Setting the Period for Closing the Shareholders’ Register or the Record Date
주주명부폐쇄기간또는기준일설정
Cell Biotech
09/12/2025
Report on the Status of Ownership of Specific Securities by Executives and Major Shareholders
임원ㆍ주요주주특정증권등소유상황보고서
윤영옥
28/11/2025
Report on the Status of Ownership of Specific Securities by Executives and Major Shareholders